References
- Kurita M, Holloway T, García-Bea A et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat. Neurosci. 15(9), 1245–1254 (2012).
- Marder E. Neuromodulation of neuronal circuits: back to the future. Neuron 76(1), 1–11 (2012).
- Borrelli E, Nestler EJ, Allis CD, Sassone-Corsi P. Decoding the epigenetic language of neuronal plasticity. Neuron 60(6), 961–974 (2008).
- Dobbs D. Schizophrenia: the making of a troubled mind. Nature 468(7321), 154–156 (2010).
- Lieberman JA, Stroup TS, McEvoy JP et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209–1223 (2005).
- Goldberg TE, Greenberg RD, Griffin SJ et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry 162, 43–48 (1993).
- Addy N, Levin ED. Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. Neuropsychopharmacology 27(4), 534–541 (2002).
- Dong E, Nelson M, Grayson DR, Costa E, Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc. Natl Acad. Sci. USA 105(36), 13614–13619 (2008).
- Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharmacol. Sci. 29(9), 445–453 (2008).
- Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 17(12), 1206–1227 (2012).
- González-Maeso J, Weisstaub NV, Zhou M et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53(3), 439–452 (2007).
- Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9(17), 3897–3902 (1998).
- Moreno JL, Sealfon SC, González-Maeso J. Group II metabotropic glutamate receptors and schizophrenia. Cell. Mol. Life Sci. 66(23), 3777–3785 (2009).
- González-Maeso J, Ang RL, Yuen T et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452(7183), 93–97 (2008).
- Fribourg M, Moreno JL, Holloway T et al. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147(5), 1011–1023 (2011).
- Casey DE, Daniel DG, Tamminga C et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology 34(5), 1330–1338 (2009).
- Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr. Serv. 55(3), 290–294 (2004).
- Meltzer HY, Bonaccorso S, Bobo WV, Chen Y, Jayathilake K. A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. J. Clin. Psychiatry 72(12), 1602–1610 (2011).
- Suzuki T, Uchida H, Takeuchi H et al. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Hum. Psychopharmacol. 24(8), 628–638 (2009).
- Kelly DL, Conley RR, Feldman S, Yu Y, McMahon RP, Richardson CM. Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr. Q. 77(1), 81–95 (2006).